Abstract
In the present experimental paradigm, we examine the effect of L-prolyl-L-leucyl-glycinamide (PLG) co-administration with haloperidol on vacuous chewing movements (VCM) in rats - a model of tardive dyskinesia (TD) in humans. We examined the dose dependent induction of VCM through both injected and orally administered PLG (MIF-1). Our results show significant levels of VCM attenuation (P<0.05) in rats treated with 10mg/kg of PLG. Doses of 1 and 100mg/kg were ineffective. Reductions were present in both orally treated and injected rats. We also examined the therapeutic effect of a peptidomimetic of PLG - PAOPA. PAOPA was able to produce similar behavioral effects to PLG at a dose, which was 100-fold lower than the effective dose of PLG. These results suggest that PLG may play a role in D2 receptor expression and function, as well as providing a therapy for neuroleptic induced TD.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 313-319 |
| Number of pages | 7 |
| Journal | Peptides |
| Volume | 24 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2003 |
Bibliographical note
Funding Information:This work was supported by NIH 20036 (USA) and NESRC (Canada).
Keywords
- (MIF-1)
- Haloperidol
- PAOPA
- PLG
- Tardive dyskinesia
- VCM